A Critical Comparison of the Evaluation of Anti-Inflammatory Therapy in Animal Models and Man

  • P. J. L. Holt
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 50 / 2)

Abstract

This chapter is purposely written from the point of view of the practising clinician in the hope that it may illustrate some of the difficulties in moving from in vitro or animal models of inflammation to the human organism and of assessing the clinical action of anti-inflammatory agents. It is primarily concerned only with the inflammation of arthritis and associated conditions which invariably form the major indication for this form of therapy.

Keywords

Placebo Toxicity Osteoporosis Corticosteroid Cyclophosphamide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Rheumatism Association: 1958 Revision of diagnostic criteria for rheumatoid arthritis. Arthr. and Rheum. 2, 16–20 (1959)CrossRefGoogle Scholar
  2. Ansell, B.M., Bywaters, E.G.L.: Alternate day corticosteroid therapy in juvenile chronic polyarthritis. J. Rheum. 1, 176–186 (1974)PubMedGoogle Scholar
  3. Backlund, L., Tiselius, P.: Objective measurements of joint stiffness in rheumatoid arthritis. Acta. rheum. scand. 13, 275–288 (1967)PubMedGoogle Scholar
  4. Beck, F.J., Whitehouse, M. W.: Effect of adjuvant disease in rats on cyclophosphamide and isophosphamide metabolism. Biochem. Pharmacol. 22, 2453–2468 (1973)PubMedCrossRefGoogle Scholar
  5. Boardman, P.J., Hart, F.D.: Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis. Brit. med. J. (1967) IV, 264–268CrossRefGoogle Scholar
  6. Chalmers, I.M., Bell, M.A., Buchanan, W.W.: Effect of flurbiprofen on the metabolism of antipyr-ine in man. Ann. rheum. Dis. 32, 58–61 (1973)PubMedCrossRefGoogle Scholar
  7. Chen, W., Vrindten, P.A., Dayton, P.C., Burns, J.J.: Accelerated amidopyrine metabolism in human subjects pretreated with phenylbutazone. Life Sci. 1, 35–42 (1962)CrossRefGoogle Scholar
  8. Cohen, A.S., Reynolds, W.E., Franklyn, E.C., Kulka, J.P., Roper, M.W., Shulman, L.E, Wallace, S.L.: Preliminary criteria for the classification of systemic lupus erythematosus. Bull, rheum. Dis. 21, 643–647 (1971)Google Scholar
  9. Collins, A.J., Ring, E.F.J., Cosh, J.A., Bacon, P.A.: Quantitation of thermography in arthritis using multi-isothermal analysis. Ann. rheum. Dis. 33, 113–115 (1974)PubMedCrossRefGoogle Scholar
  10. Co-Operating Clinics Committee of American Rheumatism Association: A controlled trial of cyclophosphamide in rheumatoid arthritis. New Engl. J. Med. 283, 883–889 (1970)CrossRefGoogle Scholar
  11. Dick, W.C.: The use of radioisotopes in normal and diseased joints. Semin. Arthr. Rheum. 1, 301–325 (1972)CrossRefGoogle Scholar
  12. Dick, W.C., Fowler, P.F.: Personal Communication (1976)Google Scholar
  13. Dickson, R.A., Nicolle, F.V.: The assessment of the rheumatoid hand. In: Holt, P.J.L. (Ed.): Current topics of Connective Tissue Diseases, pp. 95–114. London: Churchill Livingstone 1975Google Scholar
  14. Duthie, J.J.R., Thompson, M., Weir, M., Fletcher, W.B.: Medical and social aspects of the treatment of rheumatoid arthritis. Ann. rheum. Dis. 14, 133–149 (1955)PubMedCrossRefGoogle Scholar
  15. Empire Rheumatism Council: Gold therapy in rheumatoid arthritis—a report of a multicentre trial. Ann. rheum. Dis. 19, 95–119 (1960)CrossRefGoogle Scholar
  16. Feinstein, A.R.: The need for humanised science in evaluating medication. Lancet (1972)II,421–423Google Scholar
  17. Feinstein, A.R.: Clinical biostatics. XIX. Ambiguity and abuse in the twelve different concepts of ‘control’. Clin. Pharmacol. Ther. 14, 112–122 (1973)PubMedGoogle Scholar
  18. Froland, S.S., Natvig, J.B., Hoyeraal, H.M., Kass, E.: The principle of immunopotentation in rheumatoid arthritis treatment: effect of transfer factor. Scand. J. Immunol. 3, 223–228 (1974)PubMedCrossRefGoogle Scholar
  19. Gelehrter, T.D.: Enzyme induction. New Engl. J. Med. 294, 522–526, 588–595, 646–651 (1976)PubMedCrossRefGoogle Scholar
  20. Goldberg, M.A., Arnett, F.C., Bias, W.B., Shulman, L.E.: Histocompatibility antigens in systemic lupus erythematosus. Arthr. Rheum. 19, 129–132 (1976)CrossRefGoogle Scholar
  21. Hawkins, C.F., Holt, P.J.L.: The Cuffdolorimeter. Proc. roy. Soc. Med. 59 (Suppl.), 95–96 (1966)PubMedGoogle Scholar
  22. Haydu, G.G., Goldschmidt, L., Drymiotis, A.D.: Effect of imipramine on the rheumatoid factor titre of psychotic patients with depressive symptomatology. Ann. rheum. Dis. 33, 273–275 (1974)PubMedCrossRefGoogle Scholar
  23. Holt, P.J.L., How, M.J., Long, V.J.W., Hawkins, C.F.: Mucopolysaccharides in synovial fluid: effect of aspirin and indomethacin on hyaluronic acid. Ann. rheum. Dis. 27, 264–270 (1968).PubMedCrossRefGoogle Scholar
  24. Horvath, S.M., Hollander, J.L.: Intra-articular temperature as a measure of joint reaction. J. clin. Invest. 28, 469–473 (1949)CrossRefGoogle Scholar
  25. Hughes, G.R.V.: Significance of anti DNA antibodies in systemic lupus erythematosus. Lancet (1971)II,861–864Google Scholar
  26. Huskisson, E.C.: Measurement of pain. Lancet (1974)II,1127–1131Google Scholar
  27. Huskisson, E.C., Dieppe, P.A., Scott, J., Trapnell, J., Balme, H.W., Milloughby, D.A.: Immunsti-mulant therapy with levamisole for rheumatoid arthritis. Lancet (1976)I, 393–395Google Scholar
  28. Koch-Weser & Sellers, E.M.: Binding of drugs to serum albumin. New Engl. J. Med. 294, 311–315, 526–531 (1976)PubMedCrossRefGoogle Scholar
  29. Lansbury, J.: Report of a three year study on the systemic and articular indices in rheumatoid arthritis. Arthr. Rheum. 1, 505–522 (1958)CrossRefGoogle Scholar
  30. Lee, P., Baxter, A., Dick, W.C., Webb, J.: An assessment of grip strength measurements in rheumatoid arthritis. Scand. J. Rheum. 3, 17–23 (1974 a)PubMedCrossRefGoogle Scholar
  31. Lee, P., Kennedy, A.C., Anderson, J., Buchanan, W.W.: The therapeutic benefits of hospital inpatient treatment in rheumatoid arthritis. Quart. J. Med. 43, 203–214 (1974 b)Google Scholar
  32. Levi, A.J., Sherlock, S., Walker, D.: Phenylbutazone and isoniazide metabolism in patients with liver disease in relation to previous drug therapy. Lancet (1968)I, 1275–1279Google Scholar
  33. McCarty, D.J., Gatter, R.A., Steele, A.D.: A twenty pound dolorimeter for quantitation of articular tenderness. Arthr. Rheum. 11, 696–697 (1968)CrossRefGoogle Scholar
  34. Mc Conkey, B., Crockson, R.A., Crockson, A.P., Williamson, A.R.: The effect of some anti-inflammatory drugs on the acute phase proteins in rheumatoid arthritis. Quart. J. Med. 42, 785–791 (1973)Google Scholar
  35. Maini, R.N., Scott, J.T., Roffe, L.M., Hamblin, A.S., Dumonde, D.C: Preliminary experience of transfer factor in rheumatoid arthritis: clinical and immunological studies. In: Dumonde, D.C. (Ed.): Infection and Immunology in the Rheumatic Disease, pp.579–589. London: Blackwell 1976Google Scholar
  36. Medical Research Council and Nuffield Foundation: A comparison or cortisone and aspirin in the treatment of early cases of rheumatoid arthritis. Brit. med. J. (1954)I, 1223–1227Google Scholar
  37. Moertel, C.G., Taylor, W.F., Roth, A., Tyce, F.A.J.: Who responds to sugar pills? Mayo Clin. Proc. 51, 96–100(1976)PubMedGoogle Scholar
  38. Ritchie, D.M., Boyle, J.A., Mclnnes, J.H., Jasani, M.K., Dalakos, T.C., Grieveson, P., Buchanan, W.W.: Clinical studies with an articular index for assessment of joint tenderness in patients with rheumatoid arthritis. Quart. J. Med. 37, 393–406 (1968)PubMedGoogle Scholar
  39. Russell, A.S., Sturge, R.A., Smith, M.A.: Serum transaminases during salicylate therapy. Brit, med. J. (1971)II, 428–429Google Scholar
  40. Savage, O.: Measurements in rheumatoid arthritis. Proc. roy. Soc. Med. 59 (Suppl.), 85–88 (1966)PubMedGoogle Scholar
  41. Seaman, W.E., Ishak, K.C., Plotz, P.H.: Aspirin induced hepatoxicity in patients with systemic lupus erythematosus. Ann. intern. Med. 80, 1–8 (1974)PubMedGoogle Scholar
  42. Steinbrocker, O., Traeger, C.H., Batteman, R.C.: Therapeutic criteria in rheumatoid arthritis. J. Amer. med. Ass. 140, 659–662 (1949)Google Scholar
  43. Swezey, R.L.: Essentials of physical management and rehabilitation in arthritis. Semin. Arthr. Rheum. 3, 349 (1974)CrossRefGoogle Scholar
  44. Talal, N.: Immunologic and viral factors in the pathogenesis of systemic lupus erythematosus. Arthr. Rheum. 13, 887–894 (1970)CrossRefGoogle Scholar
  45. Traut, E.F., Passarell, E. W.: Placebos in the evaluation of treatment in rheumatic disease. Illinois med. J. 115, 181–198(1959)Google Scholar
  46. Verrier-Jones, J., Cumming, R.H., Bucknall, R.C., Asplin, C.M., Fraser, I.D., Bothomley, J., Davis, P., Hamblin,T.J.: Plasmophoresis in the management of acute systemic lupus erythematosus? Lancet (1976)I, 709–711Google Scholar
  47. Versey, J.M.B., Hobbs, J.R., Holt, P.J.L.: Complement metabolism in rheumatoid arthritis. 1. Longtudinal studies. Ann. rheum. Dis. 32, 357–564 (1973)Google Scholar
  48. Wright, V.: Some observations on diurnal variations of grip. Clin. Sci. 18, 17–23 (1959)PubMedGoogle Scholar
  49. Wright, V., Dowson, D., Longfield, M.D.: Joint stiffness—its characterisation and significance. Biomed.Engng 4, 8(1969)Google Scholar
  50. Wright, V., Johns, R.J.: Physical factors concerned with the stiffness of normal and diseased joints. Bull. John Hopk. Hosp. 106, 215–231 (1961)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1979

Authors and Affiliations

  • P. J. L. Holt

There are no affiliations available

Personalised recommendations